search

Active clinical trials for "Nerve Sheath Neoplasms"

Results 41-50 of 60

Combination Chemotherapy in Treating Patients With Stage III or Stage IV Malignant Peripheral Nerve...

Neurofibromatosis Type 1Sarcoma

RATIONALE: Drugs used in chemotherapy, such as doxorubicin, ifosfamide, and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving combination chemotherapy with or without radiation therapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving combination chemotherapy after surgery may kill any tumor cells that remain after surgery. PURPOSE: This phase II trial is studying how well combination chemotherapy works in treating patients with stage III or stage IV malignant peripheral nerve sheath tumors.

Completed25 enrollment criteria

Trial of Dasatinib in Advanced Sarcomas

RhabdomyosarcomaMalignant Peripheral Nerve Sheath Tumors10 more

This study will examine the response rate and the 6-month progression-free survival rates of subjects with advanced sarcoma treated with dasatinib.

Completed50 enrollment criteria

S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve...

Sarcoma

RATIONALE: Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. PURPOSE: This phase II trial is studying how well erlotinib works in treating patients with unresectable or metastatic malignant peripheral nerve sheath tumor.

Completed59 enrollment criteria

Alisertib in Treating Patients With Advanced or Metastatic Sarcoma

MyxofibrosarcomaRecurrent Adult Soft Tissue Sarcoma6 more

This phase II trial studies how well alisertib works in treating patients with sarcoma that has spread to other places in the body and usually cannot be cured or controlled with treatment (advanced) or has spread to other places in the body (metastatic). Alisertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Completed31 enrollment criteria

Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients...

Adult Alveolar Soft Part SarcomaAdult Angiosarcoma33 more

This randomized phase I/II clinical trial is studying the side effects and best dose of gamma-secretase/notch signalling pathway inhibitor RO4929097 when given together with vismodegib and to see how well they work in treating patients with advanced or metastatic sarcoma. Vismodegib may slow the growth of tumor cells. Gamma-secretase/notch signalling pathway inhibitor RO4929097 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving vismodegib together with gamma-secretase/notch signalling pathway inhibitor RO4929097 may be an effective treatment for sarcoma.

Completed37 enrollment criteria

Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma,...

Pleuropulmonary BlastomaRecurrent Malignant Peripheral Nerve Sheath Tumor4 more

This phase II trial studies how well lorvotuzumab mertansine works in treating younger patients with Wilms tumor, rhabdomyosarcoma, neuroblastoma, pleuropulmonary blastoma, malignant peripheral nerve sheath tumor (MPNST), or synovial sarcoma that has returned or that does not respond to treatment. Antibody-drug conjugates, such as lorvotuzumab mertansine, are created by attaching an antibody (protein used by the body?s immune system to fight foreign or diseased cells) to an anti-cancer drug. The antibody is used to recognize tumor cells so the anti-cancer drug can kill them.

Completed58 enrollment criteria

Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced,...

Adult AngiosarcomaAdult Desmoplastic Small Round Cell Tumor33 more

This phase I trial is studying the side effects and best dose of cixutumumab given together with doxorubicin hydrochloride and to see how well they work in treating patients with unresectable, locally advanced, or metastatic soft tissue sarcoma. Monoclonal antibodies, such as cixutumumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy, such as doxorubicin hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving monoclonal antibody cixutumumab together with doxorubicin hydrochloride may kill more tumor cells.

Completed38 enrollment criteria

Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma

LiposarcomaMalignant Peripheral Nerve Sheath Tumors3 more

The main purpose of this study is to establish a safe and tolerable dose combination (the "maximum tolerated dose") of selinexor and ixazomib when used together for the treatment of patients with certain types of advanced sarcoma. The study will enroll patients with advanced dedifferentiated liposarcoma, malignant peripheral nerve sheath tumor, alveolar soft part sarcoma and Ewing sarcoma. Future studies to further evaluate the safety and anti-cancer efficacy of this treatment for sarcoma will use the dose combination determined in this study.

Withdrawn45 enrollment criteria

Proton Radiation Therapy for Spinal Tumors

Nerve Sheath TumorsNeurofibroma

The purpose of this study is to determine if Proton Therapy can provide effective and safe treatment for Malignant Peripheral Nerve Sheath Tumors of the spine and Neurofibromas of the spine.

Withdrawn9 enrollment criteria

Study of CPI-0610 in Patients With Malignant Peripheral Nerve Sheath Tumors

Peripheral Nerve Tumors

Establish safety and toxicity profile and preliminary response rate of CPI-0610 in MPNST patients and correlate response with pharmacodynamics markers and BET inhibition.

Withdrawn26 enrollment criteria
1...456

Need Help? Contact our team!


We'll reach out to this number within 24 hrs